Patient-Reported Outcomes Following Abiraterone Acetate Plus Prednisone Added to ADT for Newly Diagnosed Metastatic Castration-Naïve Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Patient-Reported Outcomes Following Abiraterone Acetate Plus Prednisone Added to Androgen Deprivation Therapy in Patients With Newly Diagnosed Metastatic Castration-Naive Prostate Cancer (LATITUDE): An International, Randomised Phase 3 Trial
Lancet Oncol 2018 Jan 08;[EPub Ahead of Print], KN Chi, A Protheroe, A Rodríguez-Antolín, G Facchini, H Suttman, N Matsubara, Z Ye, B Keam, R Damião, T Li, K McQuarrie, B Jia, P De Porre, J Martin, MB Todd, K FizaziFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.